Clinical Data Amgen scores with new thyroid eye disease formulation PharmaphorumCan Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 8, 2026) Pharmaphorum Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster? Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA floats new clinical trial reforms; Takeda punts Denali brain drugNext: Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
